Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Stockholder's Equity - Additional Information (Details)

v3.23.1
Stockholder's Equity - Additional Information (Details) - USD ($)
 12 Months Ended
Mar. 08, 2023
Dec. 12, 2022
Nov. 08, 2022
Jul. 25, 2022
Mar. 31, 2023
Mar. 31, 2022
Apr. 19, 2023
Jun. 19, 2022
Disclosure of classes of share capital [line items]                
Number of shares authorised         492,000,000 492,000,000   492,000,000
Par value per share         $ 0.0001 $ 0.0001    
Number of shares issued         15,547,089 9,976,551    
Pre-funded warrant exercise         $ 117      
Number of shares outstanding         15,547,089 9,976,551    
Issued capital         $ 1,557 $ 999    
Related party transaction payable         18,296 126,183    
Non-cash compensation expense (included in general and administrative expense)         $ 1,734,601 $ 0    
Number of shares to be purchased by stock options issued         1,232,000      
Average price         $ 4.86      
Fair value         $ 4,143,859      
Options issued           0    
Number of stock options outstanding         1,212,000      
Nmber of stock options exercisable         0      
Shares issued for settlement of related party payable         $ 39,863 $ 452,861    
Remaining contribution to reserves         $ 109,570      
November Ordinary Warrants | March Private Placement                
Disclosure of classes of share capital [line items]                
Number of warrants cancelled 3,495,000              
Placement Agent Warrants | March Private Placement                
Disclosure of classes of share capital [line items]                
Warrants issued purchase price per share $ 1.3010              
Virax Biolabs Group Limited                
Disclosure of classes of share capital [line items]                
Cashless warrants exercised in exchange for shares         108,675      
Remaining contribution to reserves         $ 109,570      
Virax Biolabs Group Limited | Treasury Shares                
Disclosure of classes of share capital [line items]                
Number of shares issued           50,000    
Surrender amount due           $ 54,497    
Purchaser | November Private Placement                
Disclosure of classes of share capital [line items]                
Number of pre-funded warrants issued     1,165,000          
Pre-funded warrant exercise   $ 117            
Number of warrants issued     3,495,000          
Gross proceeds from issue of private placement     $ 3,844,500          
Combined purchase price per ordinary share and one and a half ordinary warrant     $ 1.65          
Combined purchase price per pre-funded warrant and one and a half ordinary warrant     $ 1.65          
Purchaser | March Private Placement                
Disclosure of classes of share capital [line items]                
Gross proceeds from issue of private placement $ 4,000,000              
Pre-funded warrants to purchase ordinary shares 2,343,309              
Purchase price per ordinary share and associated preferred options $ 1.04077              
Purchase price per pre-funded warrant and associated preferred options $ 1.04067              
Ordinary Shares                
Disclosure of classes of share capital [line items]                
Number of shares issued         15,547,089      
Number of shares outstanding         15,547,089      
Ordinary Shares | Virax Biolabs Group Limited                
Disclosure of classes of share capital [line items]                
Par value per share         $ 0.73      
Shares issued for settlement of related party payable, shares         54,300 172,532    
Number of shares issued           238,906    
Issued capital           $ 519,613    
Related party transaction payable           $ 452,861    
Cashless warrants exercised in exchange for shares         86,191      
Shares issued for settlement of related party payable         $ 149,428      
Ordinary Shares | Virax Biolabs Group Limited | Shares for Conversion of Convertible Debt                
Disclosure of classes of share capital [line items]                
Number of shares issued           37,735    
Issue of convertible instruments           $ 100,000    
Ordinary Shares | Virax Biolabs Group Limited | Services                
Disclosure of classes of share capital [line items]                
Par value per share         $ 2.65      
Number of shares issued         7,547 346,356    
Issued capital           $ 290,364    
Ordinary Shares | Purchaser | November Private Placement                
Disclosure of classes of share capital [line items]                
Number of shares issued   1,165,000 1,165,000          
Ordinary Shares | Purchaser | March Private Placement                
Disclosure of classes of share capital [line items]                
Number of shares issued 1,500,000              
Ordinary Shares | Purchaser | Major Ordinary Share Transactions | March Private Placement                
Disclosure of classes of share capital [line items]                
Number of shares issued             2,343,309  
IPO                
Disclosure of classes of share capital [line items]                
Par value per share       $ 0.0001        
Number of shares issued       1,350,000        
Ordinary shares issued price per share       $ 5.00        
Gross proceeds       $ 7,762,500        
Underwriting discounts and commissions       543,375        
Offering expenses       169,469        
Net proceeds       $ 7,049,656,000,000        
Exercise of overallotment option to purchase ordinary shares       202,500        
Class A Ordinary Shares                
Disclosure of classes of share capital [line items]                
Conversion of class B ordinary shares into class A ordinary shares               6,943,759
Class B Ordinary Shares                
Disclosure of classes of share capital [line items]                
Conversion of class B ordinary shares into class A ordinary shares               6,943,759
2022 Plan                
Disclosure of classes of share capital [line items]                
Number of shares authorised         107,418      
2023 Plan                
Disclosure of classes of share capital [line items]                
Number of shares authorised         2,500,000      
Top of Range | Placement Agent Warrants | March Private Placement                
Disclosure of classes of share capital [line items]                
Issuance of warrants to purchase ordinary shares 269,032              
Top of Range | Purchaser | November Private Placement                
Disclosure of classes of share capital [line items]                
Issuance of unregistered warrants to purchase ordinary shares     3,495,000          
Top of Range | Purchaser | March Private Placement                
Disclosure of classes of share capital [line items]                
Series A preferred investment options to purchase ordinary shares 3,497,412              
Series B preferred investment options to purchase ordinary shares 3,843,309              
Top of Range | 2022 Plan                
Disclosure of classes of share capital [line items]                
Number of shares authorised         1,319,418      
Top of Range | 2023 Plan                
Disclosure of classes of share capital [line items]                
Number of shares authorised         2,500,000